Promising Prospects in Treatment of Hepatitis B
Results of two phase III clinical studies of tenofovir alafenamib – TAF in treatment of chronic hepatitis B have been announced by the American Gilead at the International Liver Disease Congress. Tenofovir alafenamide is an investigational tenofovir prodrug. Its mechanism of action is similar to that of tenofovir. Currently tenofovir alafenamide is approved as a component of a combination HIV drug.
Studies that continued for 96 week included 1298 patients with chronic hepatitis B. Primary study endpoints were successfully achieved. They consisted of decreased hepatitis virus DNA load to <29 IU/ml. It was also shown that tenofovir alafenamib has less negative effects on bone mineral density versus Viread.
Results have been submitted to US FDA to support drug application.